VELCADE
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Amyloidosis
Conditions
Amyloidosis
Trial Timeline
Jun 1, 2005 → Sep 1, 2009
NCT ID
NCT00298766About VELCADE
VELCADE is a phase 1/2 stage product being developed by Johnson & Johnson for Amyloidosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00298766. Target conditions include Amyloidosis.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00298766 | Phase 1/2 | Completed |
Competing Products
20 competing products in Amyloidosis